These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26192307)

  • 21. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron distribution and histopathological characterization of the liver and heart of β-thalassemic mice with parenteral iron overload: Effects of deferoxamine and deferiprone.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2014 Sep; 66(7):333-43. PubMed ID: 24907196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Iron distribution and histopathological study of the effects of deferoxamine and deferiprone in the kidneys of iron overloaded β-thalassemic mice.
    Yatmark P; Morales NP; Chaisri U; Wichaiyo S; Hemstapat W; Srichairatanakool S; Svasti S; Fucharoen S
    Exp Toxicol Pathol; 2016 Sep; 68(8):427-34. PubMed ID: 27402198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ
    Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major.
    Aydinok Y; Nisli G; Kavakli K
    Br J Haematol; 1999 Jul; 106(1):252-3. PubMed ID: 10444196
    [No Abstract]   [Full Text] [Related]  

  • 27. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 28. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone.
    Loebstein R; Dalal I; Nisbet-Brown E; Berkovitch M; Meydan N; Andrews D; Loubser MD; Koren G; Roifman CM; Olivieri NF
    Br J Haematol; 1997 Sep; 98(3):597-600. PubMed ID: 9332313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry.
    Fischer R; Longo F; Nielsen P; Engelhardt R; Hider RC; Piga A
    Br J Haematol; 2003 Jun; 121(6):938-48. PubMed ID: 12786807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA; Elfaragy MS; Elrifaey SM; Abd El-Lateef AE
    Infect Disord Drug Targets; 2015; 15(3):189-95. PubMed ID: 26239735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deferiprone chelation therapy for thalassemia major.
    Galanello R; Campus S
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineral Levels in Thalassaemia Major Patients Using Different Iron Chelators.
    Genc GE; Ozturk Z; Gumuslu S; Kupesiz A
    Biol Trace Elem Res; 2016 Mar; 170(1):9-16. PubMed ID: 26179086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES; Karasmanis K; Perifanis V; Vlachaki E; Tziomalos K; Economou M
    Hemoglobin; 2014; 38(2):111-4. PubMed ID: 24351163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Fischer R; Engelhardt R
    Lancet; 2003 Jan; 361(9352):182-3; author reply 183-4. PubMed ID: 12531618
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ; Weatherall DJ
    Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical Challenges with Iron Chelation in Beta Thalassemia.
    Kwiatkowski JL
    Hematol Oncol Clin North Am; 2023 Apr; 37(2):379-391. PubMed ID: 36907610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.